Taxane Particles and Their Use
US-2016354336-A1 · Dec 8, 2016 · US
US11737972B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11737972-B2 |
| Application number | US-202218046002-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 12, 2022 |
| Priority date | Jun 9, 2017 |
| Publication date | Aug 29, 2023 |
| Grant date | Aug 29, 2023 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Disclosed herein are methods for treating epithelial cysts, including pancreatic cysts, in a subject by intracystic injection of compositions comprising antineoplastic particles, including taxane particles such as paclitaxel particles and docetaxel particles.
Opening claim text (preview).
The invention claimed is: 1. A method for treating an epithelial cyst, the method comprising injecting a composition comprising an effective amount of paclitaxel particles and an aqueous liquid carrier directly into the epithelial cyst, thereby treating the epithelial cyst, wherein the paclitaxel particles comprise at least 95% be by weight of paclitaxel, wherein the paclitaxel particles have a specific surface area (SSA) of at least 18 m 2 /g, wherein the paclitaxel particles have a mean particle size (number) of from 0.1 microns to 5 microns, wherein the composition comprises a suspension of the paclitaxel particles dispersed in the carrier, and wherein the composition does not contain ethanol. 2. The method of claim 1 , wherein the aqueous liquid carrier comprises 0.9% saline solution. 3. The method of claim 1 , wherein the aqueous liquid carrier comprises a surfactant. 4. The method of claim 3 , wherein the surfactant is a polysorbate. 5. The method of claim 4 , wherein the polysorbate is polysorbate 80 , and wherein the polysorbate 80 is present in the aqueous carrier at a concentration of between about 0.01% v/v and about 1% v/v. 6. The method of claim 1 , wherein the composition further comprises a diluent, wherein the aqueous liquid carrier and the diluent form a mixture, and wherein the composition is a suspension of the paclitaxel particles dispersed in the aqueous liquid carrier/diluent mixture. 7. The method of claim 6 , wherein the diluent comprises 0.9% saline solution. 8. The method of claim 1 , wherein the paclitaxel particles have a bulk density (not tapped) of 0.05 g/cm 3 to 0.15 g/cm 3 . 9. The method of claim 1 , wherein the concentration of the paclitaxel particles in the composition is between about 6 mg/mL and about 15 mg/mL. 10. The method of claim 1 , wherein the paclitaxel particles have a mean particle size (number) of from 0.1 microns to 1.5 microns. 11. The method of claim 1 , wherein the paclitaxel particles are crystalline particles. 12. The method of claim 1 , wherein the composition and paclitaxel particles exclude albumin. 13. The method of claim 1 , wherein cyst fluid is withdrawn from the epithelial cyst prior to injecting the composition. 14. The method of claim 13 , wherein the volume of the composition injected into the epithelial cyst is equal to the volume of cyst fluid removed from the epithelial cyst. 15. The method of claim 1 , wherein the epithelial cyst is a pancreatic cyst. 16. The method of claim 15 , wherein the pancreatic cyst is a mucinous pancreatic cyst. 17. The method of claim 1 , wherein the injecting of the composition is conducted by endoscopic ultrasound-guided fine needle injection (EUS-FNI). 18. The method of claim 1 , wherein the epithelial cyst is reduced in volume/size, is eliminated, or is ablated after injection of the composition, and/or wherein pain associated with the epithelial cyst is reduced.
Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title
for locating instruments · CPC title
in body cavities or body tracts, e.g. by using catheters · CPC title
Dispersions; Emulsions · CPC title
Emulsions {; Emulsion preconcentrates; Micelles (composition of emulsions A61K47/00)} · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.